Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care.
3 contributing indexes 4 score components composite score.
Canonical asset packet first: fundamentals, macro index exposure, entry value, and active narrative alignment. Driver rows link back to the public index that moved the score.
| Index | Driver | Reason | Weight | Condition | Contribution | As Of |
|---|---|---|---|---|---|---|
| RQRI | Risk-Quality Rotation Index | defensive quality | 5% | defensive quality — tailwind Moderate signal—/100Tailwind +1.30σ | +0.046 | 2026-05-22 |
| BPHI | Biotech & Pharma Health Index | biotech health innovation | 17% | biotech health innovation — tailwind Near normal—/100Tailwind +0.13σ | +0.031 | 2026-05-22 |
| CRSI | Credit Spread Intensity Index | credit spreads | 7% | credit spreads — headwind Near normal—/100Headwind -0.27σ | -0.026 | 2026-05-22 |
